Apogee Therapeutics에 대한 매도 수량은 투자자에게 Apogee Therapeutics의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Apogee Therapeutics (NASDAQ:APGE) 주식, 공매도 수량 보고

Apogee Therapeutics

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Equities

Mid Cap

News

Movers

General

APGE

CRNX

JOBY

KYMR

LNTH

PLUG

SMMT

XPEV

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 퀀텀스케이프(NYSE:QS)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 전고체 배터리 산업화 계약을 체결했다고 발표한 후 64.34% 급등했다.

샤오펑 및 퀀텀스케이프는 지난주 최고 성과를 보여준 11개 중형주 중 일부(7월 7일-7월 13일)

Apogee Therapeutics Inc

Barclays analyst Alex Scott upgrades Skyward Specialty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKWD#NASDAQ">SKWD</a>) from Equal-Weight to Overweight and raises the price target from $53 to $63.

Upgrades

Price Target

Analyst Ratings

SKWD

Barclays Upgrades Skyward Specialty to Overweight, Raises Price Target to $63

WIIM

Pilgrim's Pride shares are trading higher after the company announced a special dividend and provided strategy updates including investment plans, brand growth, and retail expansion.

Barclays analyst Brandt Montour initiates coverage on United Parks &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRKS#NYSE">PRKS</a>) with a Equal-Weight rating and announces Price Target of $50.

Initiation

PRKS

Barclays Initiates Coverage On United Parks & Resorts with Equal-Weight Rating, Announces Price Target of $50

Heidmar Maritime Holdings Corp. ("Heidmar") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HMR#NASDAQ">HMR</a>), announces the expansion of its service offering to include commercial management services for the offshore sector. The Company will act on behalf of a client for a five-year contract to provide a platform supply vessel (PSV) and crew for supply tours in the North Sea. The contract also has three one-year extension options.

Heidmar Maritime Announces The Expansion Of Its Service Offering To Include Commercial Management Services For The Offshore Sector; Will Act On Behalf Of A Client For A 5-Year Contract To Provide A Platform Supply Vessel And Crew For Supply Tours In The North Sea; The Contract Also Has Three 1-Year Extension Options

SCHW

Charles Schwab shares are trading higher after the company announced a year-over-year increase in core new assets and total client assets for February.

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/14061342/AjisenW.png" alt="" class="wp-image-7889" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/14061342/AjisenW.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/14061342/AjisenW-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/14061342/AjisenW-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The once-dominant ramen house's business has slumped on a mix of intensifying competition and lower consumer spending
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>Ajisen said it lost up to 40 million yuan in 2024, reversing a profit of 180 million yuan in the previous year</li>
<li>The former ramen noodle king's store count sank to 575 in the first half of 2024 from a peak of 799 in 2019</li>
</ul>
Chinese diners are notoriously fickle, with today's hot restaurant often ending as yesterday's leftovers in as little as a year. The country's latest "consumption downgrade" as consumers rein in their spending in favor of cheap eats is only making matters worse, especially for choices considered higher end.
One such chain falling victim to such trends is&nbsp;Ajisen (China) Holdings Ltd.&nbsp;(0538.HK), once hailed as a pioneer of Japanese-style ramen in China. On March 5, the restaurant operator&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0305/2025030501906.pdf">warned</a>&nbsp;that it floated into the red last year with a loss of up to 40 million yuan ($5.51 million), reversing a profit of 180 million yuan in 2023. It blamed its sinking fortunes on revaluation losses on investment properties and lower profitability in the restaurant business.
The revaluation losses related to the weak property market in Hong Kong and on the Chinese Mainland, its two main markets. It said the broader restaurant business is being adversely affected by intensified competition and changes in consumer behavior. It said revenue from its traditional dine-in business has decreased. At the same time, rising demand for takeaway services has increased operating costs, leading to a decline in overall profitability.
Ajisen first sank into the red in the first half of 2024. Its midyear report showed its revenue fell 6.6% year-on-year in the first six months of 2024 to 820 million yuan. It reported a loss of 7.16 million yuan for the period, reversing a profit of 130 million yuan in the same period of 2023. Its shares have taken a bath as its performance slipped, slumping around 25% over the past year to hover around the HK$0.80 level.
<h4 class="wp-block-heading">Erratic bottom line</h4>
The move into the red isn't new for Ajisen, whose profitability has been erratic in the last five years. The company recorded a profit of 160 million yuan in 2019, only to report a loss of 78 million yuan the next year. It returned to the black with a profit of 21 million yuan in 2021, followed by a loss of 140 million yuan in 2022 and finally a profit of 180 million yuan again in 2023.
The chain's ability to keep clawing its way back to profits may owe partly to its continuous cost reduction and improved efficiency. Its ingredient costs as a percentage of revenue dropped to 24.4% in 2023 from 26.2% in 2022, while labor costs decreased from 29.8% to 26.2% over that time, and other operating costs fell from 26.3% to 25%.
But will such cost-cutting and efficiency improvements be enough to counter the longer-term headwinds?
Originally from Japan, Ajisen was first introduced to Hong Kong in 1996 by local entrepreneur Poon Wei. After succeeding in the city, she opened the first Ajisen on the Chinese Mainland in 1998 in Shenzhen, and then expanded rapidly across the country. In 2007, the company made a Hong Kong IPO, achieving a market capitalization of more than HK$20 billion ($2.57 billion), earning Poon the nickname of "Ramen Queen".
At its peak in 2010, Ajisen floated a plan to have 1,000 stores in Mainland China within five years. But then the company got mired in a "Bone Broth" scandal in 2011, as people discovered its famous broth that it claimed was the product of 20 hours of simmering was actually made from a concentrate. That greatly tarnished Ajisen's image, taking it years to recover.
<h4 class="wp-block-heading">Rise of new Chinese-style noodle houses</h4>
That incident marked a turning point for the company, following its years on the rise. Starting in 2010, other ramen brands such as Ichiran, Kagetsu Arashi and Butao started coming to China, giving consumers more choices. As they provided more options, the once dominant Ajisen's stagnating brand began to look stale.
Targeting the mid- to high-end of the market, with bowls of noodles costing more than 40 yuan, Ajisen carved out a place mainly serving white-collar workers in shopping centers and office buildings. But people gradually came to feel its dining experience and meal quality didn't seem to merit its relatively high prices. "It looks like fast food but isn't cheap" some netizens commented.
Following the initial influx of new ramen chains, a number of new Chinese noodle houses stirred up the competition even more starting around 2020. Higher-end brands, such as Hefu, Majiyong, Chenxianggui and Zhanglala debuted and immediately became favorites of both diners and investors. Hefu completed six funding rounds, and at one time was rumored to be planning a Hong Kong IPO. Such new challengers further squeezed Ajisen's market share.
These newcomers are also suffering under the latest "consumption downgrade" in China's slowing economy. White-collar office workers no longer want to spend more money on high-end noodles, leaving such eateries high and dry. According to business registry Qichacha, China registered 31,000 new noodle houses in the first five months of last year, while 29,000 were de-registered after closing. That net growth was lower than in previous years, showing growing pressure on the group.
Meantime, Ajisen never reached its grand plan for 1,000 stores. Its count peaked at 799 in 2019 and has been falling ever since, down to 562 by 2023. Things stabilized last year and the count grew slightly to 575 in the first half of 2024. But the chain is still far from its peak in 2019, and the earlier 1,000-store target now seems like a distant dream.
Despite its stock declines, Ajisen's shares still trade at a relatively savory price-to-earnings (P/E) ratio of about 20 times, higher than the 14 for&nbsp;Jiumaojiu&nbsp;(9922.HK) and 13.5 of&nbsp;Tai Hing Group&nbsp;(6811.HK). That means investors may still see value in the stock, even if such a ratio doesn't appear to match the company's performance, leaving it at risk of appearing overvalued.
At the end of the day, the future for this pioneer and former superstar of China's restaurant scene looks increasingly cloudy. In the face of challenges from brand stagnation, intensifying competition and consumer caution, cost controls seem inadequate to revive its fortunes, and a bigger overhaul, including a rebranding, looks necessary. But whether this former "Ramen Queen" can revive her fortunes remains to be seen.

Asia

Restaurants

China's Consumption Downgrade Claims Yet Another Victim - Ajisen

Barclays analyst Brandt Montour initiates coverage on Six Flags Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>) with a Overweight rating and announces Price Target of $41.

Barclays Initiates Coverage On Six Flags Entertainment with Overweight Rating, Announces Price Target of $41

Lifeway Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWAY#NASDAQ">LWAY</a>) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.21 by 104.76 percent. This is a 103.85 percent decrease over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $46.93 million which missed the analyst consensus estimate of $48.00 million by 2.22 percent. This is a 11.50 percent increase over sales of $42.09 million the same period last year.

Earnings

LWAY

Lifeway Foods Q4 EPS $(0.01) Misses $0.21 Estimate, Sales $46.93M Miss $48.00M Estimate

Visionary Holdings shares are trading higher after the company announced that the $1 billion financing by Alfardan Group has entered the loan process.

IPAR

Coach And Interparfums Renew Partnership For Additional Five-Year Period

GRWG

GrowGeneration shares are trading lower after the company reported Q4 financial results and missed its adjusted EPS and revenue estimates.

A <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43219158/trumps-world-liberty-financial-crypto-venture-amasses-over-388-million-in-digital-assets">decentralized finance project</a> associated with U.S. President Donald Trump has raised 550 million dollars in its latest token sale, bringing total fundraising to 590 million dollars.
The initiative, known as World Liberty Financial, is focused on promoting dollar-backed stablecoins and decentralized financial applications.
World Liberty Financial recently completed the sale of 5 billion WLFI tokens, representing 25 percent of its total 100 billion supply, <a href="https://www.theblock.co/post/346331/trump-backed-world-liberty-financial-concludes-550-million-public-token-sale?utm_source=rss&amp;utm_medium=rss">according</a> to The Block.
According to co-founder Zak Folkman, the project intends to release up to 63 percent of its total supply in future sales.
The project initially launched a public sale in October 2024, selling 20 billion tokens at 1.5 cents each. By January 2025, this sale had generated 300 million dollars. 
Following this, another 5 billion tokens were made available at 5 cents per token, raising an additional 250 million dollars.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44303516/xrp-spikes-4-as-ripple-gains-approval-to-offer-crypto-payments-in-dubai">XRP Spikes 4% As Ripple Gains Approval To Offer Crypto Payments In Dubai</a>
<h3 class="wp-block-heading">Market Demand And Investor Interest</h3>
The early token sales experienced slow demand, but interest increased after Trump and Melania Trump introduced their own meme coins, which fueled curiosity in Trump-affiliated crypto ventures.
Several high-profile investors have backed World Liberty Financial. 
In November 2024, Tron (CRYPTO: TRON) founder Justin Sun contributed 30 million dollars, leading to his appointment as an advisor to the project. 
In January 2025, Web3Port, an investment platform, also committed 10 million dollars.
<h3 class="wp-block-heading">Governance And Token Restrictions</h3>
Holders of the WLFI token can participate in governance decisions related to the project. 
However, the tokens do not represent financial ownership in any entity, and transfers are restricted for the first 12 months after issuance.
<h3 class="wp-block-heading">Trump's Role In The Project</h3>
Although Trump is named as the chief crypto advocate on the project's website, and his sons—Eric, Donald Jr., and Barron—are listed as members, the official white paper states that the Trump family does not own or manage World Liberty Financial.
As the project progresses, its alignment with Trump's pro-crypto stance and the broader push for decentralized finance could influence future investor sentiment. 
With plans for additional token sales, the market will be watching closely to see how the initiative evolves.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44300120/binance-ceo-richard-teng-hails-donald-trumps-bitcoin-reserve-xrp-ethereum-solana-digital-asset-stockpile">Binance CEO Richard Teng Hails Donald Trump&#8217;s Bitcoin Reserve, XRP, Ethereum, Solana Digital Asset Stockpile</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$TRUMP

Trump-Backed World Liberty Financial Raises $590M In Token Sales

Gregory and Scott Fortunoff, who together with their affiliates, hold a substantial equity interest in James River Group Holdings, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRVR#NASDAQ">JRVR</a>) (the "Company"), sent the following letter to the Company's Board of Directors (the "Board") regarding the Board's recent decision to significantly increase the cash incentive awards for Company management for the 2024 performance period despite the Company's ongoing underperformance.

Management

JRVR

Gregory and Scott Fortunoff Sends Letter To James River Group Holdings Regarding The Board's Recent Decision To Significantly Increase The Cash Incentive Awards For Co Management For The 2024 Performance Period Despite The Co's Ongoing Underperformance

Financing

Visionary Holdings Says The $1B Financing By Alfardan Group Has Now Entered The Loan Process And Is Expected To Be In Place Soon

Rumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>), the video-sharing platform and cloud services provider, today unveiled Rumble Live, a linear livestreaming lineup of dynamic creator content that will take viewers through the entire day without having to visit any other place for their news, commentary, and entertainment. Rumble is reimagining the video platform experience by offering a format in which shows use the Rumble Raiding technology to follow one another and carry audiences seamlessly into the next show. Each show will also appear on the creators' individual Rumble channels.
In addition to the Rumble Live lineup, many creators including Steven Crowder, will voluntarily cut off their YouTube livestreams on March 24th and exclusively stream on Rumble.
The daytime lineup has been set, with the afternoon and evening programming to be announced soon.
Rumble Live Daytime Lineup (all times Eastern time zone)
<figure class="table"> 
<table>
<tbody>
<tr>
<td>9:00 a.m.</td>
<td>Evita Duffy-Alfonso</td>
</tr>
<tr>
<td>10:00 a.m.</td>
<td>Vince Coglianese</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>Steven Crowder</td>
</tr>
<tr>
<td>12:00 p.m.</td>
<td>Tim Pool</td>
</tr>
<tr>
<td>1:00 p.m.</td>
<td>Russell Brand</td>
</tr>
<tr>
<td>2:00 p.m.</td>
<td>The Quartering</td>
</tr>
<tr>
<td>4:00 p.m.</td>
<td>Viva Frei</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Rumble Introduces Its Rumble Live Streaming Lineup Including Tim Pool And Russell Brand Among Others

NKTR

Nekar Therapeutics shares are trading higher after Oppenheimer upgraded the stock from Perform to Outperform and announced a price target of $6.

MLGO

MicroAlgo Announced That Their Research And Development Team Improved Stability And Practicality Of Algorithm By Optimizing The Quantum Circuit Design

BZAI

Blaize Holdings Partners With Turbo Federal To Help Blaize Establish Relationships And Establish Technology In Federal Use Cases

CLLS

Collectis shares are trading higher after the company reported better-than-expected Q4 financial results.

Throughout the last three months, 19 analysts have evaluated Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $450.95, a high estimate of $538.00, and a low estimate of $364.00. Witnessing a positive shift, the current average has risen by 0.81% from the previous average price target of $447.32.
<img src="https://www.benzinga.com/files/images/story/2025/1741957263_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Ulta Beauty among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$400.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$380.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$364.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$460.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$460.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$500.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$500.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$445.00</td>
<td>$410.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$480.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$538.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Kelly Crago</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$457.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$475.00</td>
<td>$460.00</td>
</tr>
<tr>
<td>Anna Glaessgen</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$430.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$475.00</td>
<td>$455.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$370.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$425.00</td>
<td>$394.00</td>
</tr>
<tr>
<td>Rupesh Parikh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$515.00</td>
<td>$505.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$500.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$394.00</td>
<td>$390.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ulta Beauty. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ulta Beauty compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Ulta Beauty's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Ulta Beauty's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ULTA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ulta Beauty analyst ratings.</a>
<h2>Discovering Ulta Beauty: A Closer Look</h2>
With more than 1,400 freestanding stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the US. The firm offers makeup (41% of 2023 sales), fragrances, skin care (19% of sales), and hair care products (19% of sales), and bath and body items. Ulta offers private-label products and more than 600 individual brands. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. The firm intends to open franchises in Mexico in 2025. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
<h3>Ulta Beauty: A Financial Overview</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Ulta Beauty displayed positive results in 3 months. As of 31 October, 2024, the company achieved a solid revenue growth rate of approximately 1.65%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.57%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Ulta Beauty's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.36% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.14%, the company showcases effective utilization of assets.
Debt Management: Ulta Beauty's debt-to-equity ratio is below the industry average at 0.92, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ULTA

Beyond The Numbers: 19 Analysts Discuss Ulta Beauty Stock

Health Care

Press Releases

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

Apogee Therapeutics Announces Agenda for Virtual R&D Day

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Comments

Apogee Therapeutics

매도 수량

Apogee Therapeutics (NASDAQ:APGE) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌